DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DexCom, Inc. officer Michael Jon Brown, listed as EVP Chief Legal Compliance Off, sold 1,700 shares of common stock on October 15, 2026, at $85.48 per share. The sale was made pursuant to a Rule 10b5-1 Plan adopted November 26, 2025. His reported direct position after the sale was 98,185 shares, including 71,903 unvested restricted stock units.
Dexcom, Inc. (DXCM) officer Michael Brown filed notice of a proposed sale of 1,700 common shares, with an aggregate market value of $145,316, listing Morgan Stanley Smith Barney LLC and October 15, 2026 as the approximate sale date. The shares are identified as restricted stock acquired from the issuer on March 8, 2026. The notice lists prior sales of 1,700 shares on September 15, 2026, for $142,868, and 1,700 shares on August 14, 2026, for $156,281. The signature appears as Michael Jon Brown.
DexCom (DXCM) EVP Sadie Stern sold 2,565 shares of common stock at $86.15 per share on September 28, 2026. The sale was made under a Rule 10b5-1 plan adopted May 28, 2026, which allows the orderly disposition of shares she owns. Her directly held position after the sale was 123,478 shares.
Dexcom officer Sadie Stern gave notice of a proposed sale of 2,565 common shares, with an aggregate market value of $220,974.75 and an approximate sale date of September 28, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are identified as restricted stock acquired from Dexcom on March 8, 2024. The notice also reports Stern sold 2,565 common shares on August 27, 2026, with an aggregate market value of $226,669.05.
DEXCOM INC (DXCM) director Nicholas Augustinos reported two insider sales of Dexcom common stock that were executed indirectly through the Kirschner/Augustinos Revocable Trust, for which he is a trustee. On September 15, 2026, the trust sold 6,539 shares at $84.04 per share, and on September 14, 2026 it sold 1,550 shares at $84.02 per share. A Rule 10b5-1 trading plan adopted on June 10, 2026 governs these transactions. Separately, Augustinos holds 5,575 unvested restricted stock units directly, granted on May 28, 2026, which will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 annual meeting of stockholders.
DEXCOM INC (DXCM) executive Michael Jon Brown, EVP and Chief Legal Compliance Officer, reported selling 1,700 shares of common stock on September 15, 2026 at $84.04 per share in an open-market or private transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025.
Following this sale, Brown directly holds 99,885 shares, which includes 71,903 unvested restricted stock units scheduled to vest between March 8, 2027 and March 8, 2029, and 83 shares acquired under Dexcom’s Amended and Restated 2015 Employee Stock Purchase Plan.
DEXCOM, INC. (DXCM) officer Michael Brown filed a notice under Rule 144 to sell up to 1,700 shares of common stock through Morgan Stanley Smith Barney, reflecting an aggregate market value of $142,868.00. Dexcom reports 377,360,765 common shares outstanding, a baseline figure separate from this planned sale.
DEXCOM INC (DXCM) received a Rule 144 notice for a proposed sale of up to 6,539 shares of common stock by director Nicholas Augustinos through Fidelity Brokerage Services LLC. The shares derive from vested RSU grants dated May 8, 2026 and May 19, 2022.
The proposed sale represents an aggregate market value of $549,537.56, with 377,360,765 shares of Dexcom common stock outstanding as of September 15, 2026. In the prior three months, Augustinos sold 1,550 shares for $130,231.00 under Rule 144.
DexCom, Inc. (DXCM) reported that its Board of Directors appointed Executive Vice President and Chief Financial Officer Jereme Sylvain to the expanded role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. The move consolidates oversight of global operations, quality and finance under Mr. Sylvain.
Under an offer letter dated September 11, 2026, Mr. Sylvain will receive an annual base salary of $767,000 and an annual target bonus opportunity equal to 75% of base salary, and remains eligible for equity awards and participation in Dexcom’s existing executive severance and benefit plans.
DEXCOM INC (DXCM) reported that EVP and Chief Financial Officer Jereme M. Sylvain sold 3,638 shares of common stock on September 10, 2026 at $83.27 per share in an open-market transaction. The sale was made under a Rule 10b5-1 trading plan adopted on June 10, 2026, and he now holds 146,828 shares directly, including 87,094 unvested restricted stock units.